Merck & Co., Inc.

Merck & Co., Inc. is a U.S.-based global health care company focused on prescription medicines, vaccines, and animal health products. Its business is organized into Pharmaceutical and Animal Health, with revenue driven by branded human health therapies and preventive vaccines, plus veterinary medicines, vaccines, and connected animal health solutions.

74,8 %

28,1 %

+1,3 %

1.54

1.30

— Merck & Co., Inc.
%
Pharmaceuticals85% Human health prescription medicines used to treat and prevent disease across oncology, cardiometabolic, respiratory, immunology, virology, and other areas.
Vaccines10% Preventive vaccines for pediatric, adolescent, and adult populations sold through health systems, physicians, wholesalers, and governments.
Animal Health5% Veterinary medicines, vaccines, and health management solutions for livestock and companion animals.

Merck sells human health products mainly to drug wholesalers, retailers, hospitals, government agencies, and managed...

  • Wholesalers and retailersprimary

    Buy prescription medicines in bulk for downstream distribution and are central to Merck's U.S. channel economics and chargeback/rebate structure.

  • Hospitals and managed care organizationsprimary

    Purchase or influence access to branded therapies and vaccines through formularies, reimbursement, and contracting decisions.

  • Government and public health buyerssecondary

    Buy vaccines and certain medicines through public programs and procurement channels, especially in the U.S. and abroad.

  • Veterinarians and animal producerssecondary

    Buy animal health medicines, vaccines, and monitoring solutions to prevent and treat disease in livestock and companion animals.

  • Pet owners and companion animal channelemerging

    Purchase selected animal health products through veterinary and retail channels for preventive and therapeutic care.

Merck is a global business with operations across the U.S., Europe, Latin America, the Middle East, Africa, Eastern...

  • •U.S. is the core commercial market and major source of pricing pressure
  • •Europe is important for sales, manufacturing, and regulatory access
  • •Asia Pacific and emerging markets support long-term growth
  • •Latin America, Middle East, Africa, and Eastern Europe add expansion upside
  • •Ireland is a notable manufacturing footprint after the Dundalk facility deal

Merck's strategy centers on science-led growth through internal R&D, new product approvals, and external business...

01
Advance the pipeline in oncology, cardiometabolic, respiratory, and immunologymedium-term

Merck needs new products to offset patent expirations, pricing pressure, and declining mature franchises.

02
Use business development to supplement internal R&Dshort-term

External assets can accelerate growth and diversify the portfolio when internal discovery alone is insufficient.

03
Defend access and pricing in the U.S. marketshort-term

Rebates, chargebacks, formulary placement, and government pricing materially affect realized net sales.

04
Maintain shareholder returns while funding growthmedium-term

Merck uses operating cash flow to support dividends, repurchases, and strategic investments.

Merck's biggest risks come from patent expiry, pricing pressure, and dependence on a small number of large products...

high

Patent expiration and generic/biosimilar competition

Merck relies on patent protection to preserve exclusivity; once lost, sales can fall quickly.

Scope
Human health and animal health portfolios
Materiality
high
high

Pricing pressure and formulary access

Rebates, chargebacks, government pricing, and managed care negotiations lower realized prices.

Scope
U.S. prescription medicines and vaccines
Materiality
high
high

R&D and clinical development failure

Pipeline assets may not achieve approval or commercial success, leaving gaps after mature products decline.

Scope
Oncology, immunology, cardiometabolic, respiratory
Materiality
high
medium

Regulatory and litigation risk

Product liability, antitrust, patent disputes, and government investigations can block sales or create charges.

Scope
Global pharmaceutical operations
Materiality
medium
medium

Foreign exchange and geopolitical exposure

International sales and operations create volatility from currency moves, local regulation, and political instability.

Scope
Latin America, Middle East, Africa, Eastern Europe, Asia Pacific
Materiality
medium
Revenue deductions for rebates, chargebacks, and returns
Net revenue and quarterly comparability
Acquisition accounting and intangible valuation
Amortization, impairment risk, and earnings volatility
Milestone and upfront collaboration payments
Period earnings and cash flow timing
Restructuring and accelerated depreciation
Operating margin and comparability
Impairment of goodwill and long-lived assets
Non-cash charges and asset values

PFIZER INC

PFE · Pharmaceutical Preparations

JOHNSON & JOHNSON

JNJ · Pharmaceutical Preparations

Oscar Health, Inc.

OSCR · Hospital & Medical Service Plans

Elanco Animal Health Inc

ELAN · Pharmaceutical Preparations

GILEAD SCIENCES, INC.

GILD · Biological Products, (No Diagnostic Substances)

HCA Healthcare, Inc.

HCA · Services-General Medical & Surgical Hospitals, NEC

: 11/08/2026